Non-small cell lung cancer trials recruiting in Maryland

All Non-small cell lung cancer trials nationally

Cities in Maryland

Recruiting trials in Maryland

• A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)
  NCT06692738 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · Maryland: Baltimore, Bethesda
• A Global Study to Assess the Effects of Durvalumab + Domvanalimab Following Concurrent Chemoradiation in Participants With Stage III Unresectable NSCLC
  NCT05211895 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · Maryland: Baltimore, Silver Spring
• A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors
  NCT07020221 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · Maryland: Baltimore
• A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
  NCT06793215 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · Maryland: Baltimore
• A Study of Novel Combinations in Non-Small Cell Lung Cancer (NSCLC)
  NCT07098338 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · Maryland: Baltimore
• A Study of Pembrolizumab With or Without Chemotherapy in Combination With Additional Treatments for Advanced Non-Small Cell Lung Cancer (NSCLC) (MK-3475-01G/KEYMAKER U01)
  NCT06731907 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · Maryland: Baltimore
• A Study of [225Ac]Ac-AKY-1189 in Patients With Solid Tumors
  NCT07020117 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · Maryland: Glen Burnie
• A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%
  NCT06561386 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · Maryland: Annapolis
• A Study to Investigate Ubamatamab With and Without Marlotamig (REGN7075) in Adult Participants With Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)
  NCT07154290 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · Maryland: Baltimore
• Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
  NCT03412877 · Phase: Phase 2 · Ages: 18 Years to 72 Years · Sex: All (male and female) · Maryland: Bethesda
• Biospecimen Procurement for Center for Immuno-Oncology Immunotherapy Protocols
  NCT02682667 · Phase: Not specified · Ages: 18 Years to 120 Years · Sex: All (male and female) · Maryland: Bethesda
• Blood-brain Barrier (BBB) Opening Using Exablate Focused Ultrasound With Standard of Care Treatment of NSCLC Brain Mets
  NCT05317858 · Phase: Phase 3 · Ages: 18 Years to 100 Years · Sex: All (male and female) · Maryland: Baltimore
• Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients
  NCT05899608 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · Maryland: Baltimore
• Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1
  NCT06767514 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · Maryland: Baltimore
• Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer
  NCT05142189 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · Maryland: Baltimore
• DK222 Study at Hopkins
  NCT07140315 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · Maryland: Baltimore
• Dabrafenib and/or Trametinib Rollover Study
  NCT03340506 · Phase: Phase 4 · Ages: 18 Years to 100 Years · Sex: All (male and female) · Maryland: Bethesda
• First in Human Phase 1 Study of AG01 Anti-Progranulin/GP88 Antibody in Advanced Solid Tumor Malignancies
  NCT05627960 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · Maryland: Baltimore
• JoLT-Ca Sublobar Resection (SR) Versus Stereotactic Ablative Radiotherapy (SAbR) for Lung Cancer
  NCT02468024 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · Maryland: Annapolis, Baltimore
• KRAS-Targeted Vaccine With Chemoimmunotherapy, Nivolumab and Ipilimumab for Patients With NSCLC
  NCT05254184 · Phase: Phase 1 · Ages: 18 Years to 100 Years · Sex: All (male and female) · Maryland: Baltimore
• Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer
  NCT05061550 · Phase: Phase 2 · Ages: 18 Years to 95 Years · Sex: All (male and female) · Maryland: Baltimore
• Phase I Study of Tolododekin Alfa (ANK-101) in Advanced Solid Tumors
  NCT06171750 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · Maryland: Bethesda
• Phase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced or Metastatic Non-small Cell Lung Cancer
  NCT06350097 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · Maryland: Bethesda
• Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations
  NCT06357533 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · Maryland: Annapolis
• Prospective Non-Interventional Study Comparing Osimertinib +/- Chemotherapy for EGFR-Mutated NSCLC Patients
  NCT06538038 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female) · Maryland: Baltimore
• Prospective Trial Assessing Real World Outcomes Response to Pembro in Black Patients w/ NSCLC
  NCT06745882 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · Maryland: Baltimore, Salisbury
• Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
  NCT05579366 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · Maryland: Rockville
• SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
  NCT03452774 · Phase: Not specified · Ages: No age limits stated · Sex: All (male and female) · Maryland: Baltimore, Bethesda, Silver Spring, Towson
• Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer
  NCT06712316 · Phase: Phase 2, Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · Maryland: Frederick
• Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
  NCT06881784 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · Maryland: Baltimore
• Study of STK-012 Alone and With Other Treatments in Patients With Advanced Lung Cancer and Other Cancers
  NCT05098132 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · Maryland: Baltimore
• Study to Evaluate Sutetinib Maleate Capsule in Locally Advanced or Metastatic Non-small Cell Lung Cancer
  NCT05168566 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · Maryland: Baltimore
• Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
  NCT07222566 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · Maryland: Annapolis, Bethesda, Brandywine, Columbia
• Tissue Procurement and Natural History Study of People With Non-Small Cell Lung Cancer, Small Cell Lung Cancer, Extrapulmonary Small Cell Cancer, Pulmonary Neuroendocrine Tumors, and Thymic Epithelial Tumors
  NCT02146170 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female) · Maryland: Bethesda